It's a shame that just as things are getting exciting coming up to the release of Phase2b results and after all these years of being involved with getting Cvac to this point, another one jumps ship.....
""HealthLinx snares former Prima Biomed manager as GM for Australian operations Friday, June 29, 2012 by Angela Kean
HealthLinx (ASX: HTX) has gained the experience of former business development and intellectual property manager for Prima BioMed Vanessa Waddell with her appointment as general manager for Australian Operations.
Waddell’s experience in the immunology sector, specifically oncology and more specifically in the development of ovarian cancer therapeutics, will be invaluable to HealthLinx as it continues the development and commercialisation of its lead product, OvPlex™.""
Vanessa Waddell
Business Development and Intellectual Property Manager
""Ms Waddell is the Business Development Manager and Intellectual Property Manager of Prima BioMed. Previous industry experience includes technical specialist and product development roles with AMRAD Biotech. Prior to joining Prima BioMed, Ms Waddell was employed in the commercialisation company of the Austin Research Institute. Since joining Prima BioMed, Ms Waddell has overseen project management of the company's first two investments, Cancer Vac Ltd and Arthron Ltd. In addition she has assisted in the identification, evaluation and structuring of two further investments made by the company. Ms Waddell has a BSc (Hons) degree in Science from the University of Sydney and a Masters of Business Administration from Deakin University.""
PRR Price at posting:
9.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)